Meds & Biologics
Entyvio and Remicade are the two most commonly used intravenous biologics for Crohn's disease, but they take very different approaches to quieting gut inflammation. Remicade is a broad anti-tumor necrosis factor (anti-TNF) agent that affects inflammation throughout the body. Entyvio is a gut-selective biologic that acts almost exclusively on the intestines. For patients who want the convenience of infusion therapy but are weighing systemic vs targeted action, this is a common comparison. This guide walks through the evidence on entyvio vs remicade crohn's across mechanism, efficacy, safety, and practical considerations.
Anti-TNF vs Gut-Selective Mechanism
Remicade (infliximab) is a chimeric monoclonal antibody that binds and neutralizes TNF-alpha, a cytokine that drives inflammation throughout the body and within the gut. Because TNF-alpha is widely active, blocking it produces effects beyond the intestine, including benefits for joint and skin manifestations of Crohn's but also broader immune suppression. Entyvio (vedolizumab) works on a different target. It binds the alpha-4-beta-7 integrin, a receptor found almost exclusively on gut-homing lymphocytes. By blocking those cells from entering inflamed intestinal tissue, vedolizumab quiets gut inflammation without meaningfully suppressing the immune system elsewhere. For patients the gut-selective vs anti-TNF decision often centers on how much systemic immunosuppression they are willing to accept.
Induction Efficacy: Remicade Often Works Faster
In randomized trial data, Remicade has shown stronger induction efficacy in Crohn's disease. A 2022 systematic review and meta-analysis of infliximab and vedolizumab therapy found that infliximab produced better outcomes than vedolizumab during the induction phase for Crohn's disease (Wu et al., BMC Gastroenterology 2022). Entyvio's onset is notably slower. The Entyvio label instructs clinicians to wait until week 14 before deciding whether the drug is working, compared to Remicade's typical assessment point around week 8. For patients with active moderate-to-severe disease who need rapid symptom control, most gastroenterologists lean toward Remicade or another anti-TNF as the faster induction option. Patients who can tolerate a slower ramp-up may do fine starting on Entyvio.
Maintenance Efficacy: Similar Over Time
Over the maintenance phase the gap narrows. The same meta-analysis found that similar proportions of infliximab- and vedolizumab-treated patients achieved clinical response, remission, and mucosal healing during maintenance. The EVOLVE study, a real-world cohort of biologic-naive Crohn's patients, reported no significant differences in 12-month clinical effectiveness between the two drugs and higher drug persistence rates for vedolizumab at 12 and 24 months (EVOLVE, PMC10833200). Higher persistence means fewer patients discontinuing, which often reflects tolerability more than pure efficacy. For biologic-naive patients willing to wait through a slower induction, Entyvio delivers comparable long-term outcomes to Remicade in real-world practice.
Safety and Infection Risk
This is the area where Entyvio offers a meaningful advantage for many patients. Entyvio's gut-selective mechanism translates into lower rates of systemic infection and a more favorable long-term safety profile than anti-TNFs overall. In the 2022 meta-analysis, rates of adverse events and serious adverse events were similar between the two drugs, but vedolizumab had a cleaner profile for opportunistic infections, malignancy, and demyelinating disease. A 2024 Swedish registry study of Crohn's patients did find a higher rate of serious gastrointestinal infections on vedolizumab compared to anti-TNFs, which is worth noting, though overall systemic infection risk was lower. For entyvio vs remicade side effects, infusion reactions and antidrug antibody formation are more common with Remicade, and patients often take it with an immunomodulator to reduce immunogenicity. Entyvio is typically used as monotherapy.
Dosing and Infusion Experience
Both drugs share the infusion-based starting point. Remicade induction is three IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks at 5 mg/kg, with dose escalation to 10 mg/kg available for patients who lose response, per Janssen's Remicade information. Remicade infusions typically run two hours or longer. Entyvio uses a flat 300 mg dose with the same week 0, 2, and 6 induction schedule and every-8-week maintenance, but infusions run closer to 30 minutes, according to Takeda's dosing information. Patients who respond to Entyvio by week 6 can switch to a 108 mg subcutaneous pen every 2 weeks, which eliminates the infusion center commitment. That SC option is not available for Remicade.
Cost and Access
Both drugs are expensive biologics. Remicade infusions typically cost between three and twelve thousand dollars per treatment, depending on weight-based dosing and facility fees. Entyvio's flat dose costs closer to $4,300 per infusion, per commonly cited figures. Biosimilars for Remicade, including Inflectra (infliximab-dyyb) and Renflexis (infliximab-abda), have widely reduced out-of-pocket costs and are often the preferred option on insurance formularies. No vedolizumab biosimilar is yet available in the US, so Entyvio access depends entirely on your plan's coverage of the branded drug. For patients optimizing for cost, Remicade biosimilars are often the clearer winner; for patients optimizing for safety, Entyvio is typically preferred.
Making the Decision
There is no single correct answer in the entyvio vs remicade crohn's choice. Remicade tends to win on induction speed, dose escalation flexibility, and biosimilar cost savings. Entyvio tends to win on long-term safety, simpler monotherapy, shorter infusions, and subcutaneous conversion options. Your gastroenterologist will weigh disease severity, comorbidities, prior biologic exposure, and insurance coverage. For patients who have already failed an anti-TNF, Entyvio is often a reasonable next step because of the mechanism change. For patients with severe or fistulizing disease, Remicade usually remains a first-line choice. Before starting either drug, ask your GI about the expected timeline to response, what monitoring labs will be run and how often, and whether therapeutic drug monitoring will be part of your care plan. A consistent log of symptoms, bowel movements, and any new infections between visits gives your care team the data to adjust dosing or switch classes early rather than waiting for a full flare.